These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31126115)

  • 1. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice.
    Nakaoku Y; Saito S; Yamamoto Y; Maki T; Takahashi R; Ihara M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease.
    Kosaraju J; Holsinger RMD; Guo L; Tam KY
    Mol Neurobiol; 2017 Oct; 54(8):6074-6084. PubMed ID: 27699599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.
    Gault VA; Lennox R; Flatt PR
    Diabetes Obes Metab; 2015 Apr; 17(4):403-13. PubMed ID: 25580570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans.
    Batchu SN; Yerra VG; Liu Y; Advani SL; Klein T; Advani A
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32796688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.
    Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
    Vascul Pharmacol; 2016 Apr; 79():16-23. PubMed ID: 26277250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy.
    Sharkovska Y; Reichetzeder C; Alter M; Tsuprykov O; Bachmann S; Secher T; Klein T; Hocher B
    J Hypertens; 2014 Nov; 32(11):2211-23; discussion 2223. PubMed ID: 25215436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DPP-4 inhibition by linagliptin ameliorates age-related mild cognitive impairment by regulating microglia polarization in mice.
    Zhuge F; Zheng L; Pan Y; Ni L; Fu Z; Shi J; Ni Y
    Exp Neurol; 2024 Mar; 373():114689. PubMed ID: 38199510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho-/- mice.
    Hasegawa Y; Hayashi K; Takemoto Y; Cheng C; Takane K; Lin B; Komohara Y; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2017 Dec; 16(1):154. PubMed ID: 29195509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice.
    Kanda J; Furukawa M; Izumo N; Shimakura T; Yamamoto N; Takahashi HE; Wakabayashi H
    Drug Discov Ther; 2020 Nov; 14(5):218-225. PubMed ID: 33116039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-angiogenic effects of the DPP-4 inhibitor linagliptin via inhibition of VEGFR signalling in the mouse model of oxygen-induced retinopathy.
    Kolibabka M; Dietrich N; Klein T; Hammes HP
    Diabetologia; 2018 Nov; 61(11):2412-2421. PubMed ID: 30097694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model.
    Wang SC; Wang XY; Liu CT; Chou RH; Chen ZB; Huang PH; Lin SJ
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dipeptidyl peptidase 4 inhibition on inflammation in atherosclerosis: A
    Virta J; Hellberg S; Liljenbäck H; Ståhle M; Silvola JMU; Huusko J; Söderström M; Knuuti J; Nuutila P; Ylä-Herttuala S; Gomez MF; Roivainen A; Saraste A
    Atherosclerosis; 2020 Jul; 305():64-72. PubMed ID: 32386751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
    Takashima S; Fujita H; Fujishima H; Shimizu T; Sato T; Morii T; Tsukiyama K; Narita T; Takahashi T; Drucker DJ; Seino Y; Yamada Y
    Kidney Int; 2016 Oct; 90(4):783-96. PubMed ID: 27475229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
    Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
    Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice.
    Ma M; Hasegawa Y; Koibuchi N; Toyama K; Uekawa K; Nakagawa T; Lin B; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2015 May; 14():54. PubMed ID: 25986579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase-4 inhibitor Linagliptin: A subanalysis from a randomized, placebo-controlled trial (RELEASE study).
    de Boer SA; Reijrink M; Abdulahad WH; Hoekstra ES; Slart RHJA; Heerspink HJL; Westra J; Mulder DJ
    Diabetes Obes Metab; 2020 Jul; 22(7):1220-1225. PubMed ID: 32166899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.
    Groop PH; Cooper ME; Perkovic V; Sharma K; Schernthaner G; Haneda M; Hocher B; Gordat M; Cescutti J; Woerle HJ; von Eynatten M
    Diab Vasc Dis Res; 2015 Nov; 12(6):455-62. PubMed ID: 26224765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
    Yamaguchi T; Watanabe A; Tanaka M; Shiota M; Osada-Oka M; Sano S; Yoshiyama M; Miura K; Kitajima S; Matsunaga S; Tomita S; Iwao H; Izumi Y
    J Pharmacol Sci; 2019 Feb; 139(2):112-119. PubMed ID: 30638989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.
    Darsalia V; Olverling A; Larsson M; Mansouri S; Nathanson D; Nyström T; Klein T; Sjöholm Å; Patrone C
    Regul Pept; 2014 May; 190-191():25-31. PubMed ID: 24821550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.
    Biessels GJ; Janssen J; van den Berg E; Zinman B; Espeland MA; Mattheus M; Johansen OE;
    BMC Neurol; 2018 Jan; 18(1):7. PubMed ID: 29334906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.